Compare Moody's Corporation (MCO) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moody's Corporation vs TransMedics Group Inc — how do they compare? Moody's Corporation trades at $464.23 (market cap $79.44B), while TransMedics Group Inc trades at $77.87 (market cap $2.74B). The key difference: Moody's Corporation is far larger — about 29× TransMedics Group Inc's market cap, and Moody's Corporation pays a 0.9% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Moody's Corporation for 132 Days and TransMedics Group Inc for 24 Days on average.
| MCO | TMDX | |
|---|---|---|
Market Cap | $79.44B | $2.74B |
Volume | 526,684 | 949,331 |
Sector | Financials | Health |
52-Week High | $539.61 | $150.42 |
52-Week Low | $412.23 | $61.99 |
Typical Hold Time | 132 Days | 24 Days |
Enterprise Value | $85.46B | $3.13B |
Dividend Yield | 0.9% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MCO trades at $458.69, up 2.01% today, with a bearish technical signal but strong fundamentals including 34.25% net income margin and 80.15% ROE. Recent earnings beats and a consensus price target of $536.40 suggest upside potential. The company announced a minority stake in PhilRatings and a new credit risk model with Allvue, expanding its Asia-Pacific presence and product offerings.
Outlook is positive given consistent earnings growth and strategic expansions, though high valuation multiples and bearish technical indicators near-term pose risks. Analyst consensus is bullish with 56% buy ratings, but investors should monitor debt levels and macroeconomic sensitivity.
TMDX trades at $79.00, down 2.55% amid bearish technical signals. The stock shows strong profitability with 22.69% net margin and 36.28% ROE, though recent earnings misses and margin compression from 2025 to 2026 raise concerns. Analyst consensus remains bullish with a $99.75 price target, but multiple legal investigations into fiduciary duties create uncertainty. Revenue growth continues with 2026 guidance at $668M.
The stock presents a growth opportunity with analyst upside potential, but faces near-term headwinds from earnings volatility and legal scrutiny. Execution on 2026 guidance and resolution of governance concerns will be critical for sustained momentum. Current valuation at 20.47 P/E appears reasonable given growth prospects if operational targets are met.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Moody's Corporation
Moody's, along with S&P Ratings, is a leading provider of credit ratings on fixed income securities. Moody's ratings segment, known as Moody's Investors Service or MIS, includes corporates, structured finance, financial institutions, and public finance ratings. MIS represents a majority of the firm's revenue and profits. Moody's other segment is Moody's Analytics and consists of Research, Data, and Analytics or RD&A and Enterprise Risk Solutions or ERS. RD&A's products include credit research, quantitative credit scores, economic research, business intelligence, know your customer (KYC) tools, commercial real estate data and analytical tools, and training services. ERS includes risk management software solutions to financial institutions.
Read more on MCO →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
